A STUDY OF ASP2215 (GILTERITINIB), ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING INDUCTION/CONSOLIDATION THERAPY FOR SUBJECTS WITH FMS-LIKE TYROSINE KINASE 3 (FLT3/ITD) ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION: